Skip navigation

Strategies and Best Practices to Strengthen Program Compliance and Integrity in an Evolving Regulatory Landscape

August 21-22, 2018
  • Washington, DC

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 4th Annual 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes, and establish best practices to collaborate with contract pharmacies and covered entities.

Along with convening 340B manufacturers, CBI’s summit is also the only event to convene manufacturers and covered entities within our Closed-Door Collaboration Summit to discuss innovative methods to work together under the 340B program.

Don’t miss out on the industry’s premiere event to propel collaborative initiatives, adhere to new and evolving regulatory guidance and mitigate risk within a highly complex market.

Critical Updates, Interactive Discussions
and Valuable Takeaways:

  • Gain key insights on 340B program developments and
    anticipated future rulings
  • Improve understanding of self-disclosure letters to
    effectively respond and resolve financial discrepancies
  • Discuss covered entity and pharmacy challenges and
    best practices for collaboration
  • Hear relevant case studies on manufacturer successes
    and lessons learned related to implementing new guidance
    and price calculations
  • Explore auditing best practices to pinpoint payment
    discrepancies and maintain strong covered entity relationships
  • Interpret HRSA guidance and government regulations to
    define patients and calculate AMP and best price

CBI’s 340B Manufacturer Summit hosts the 340B Closed-Door Collaboration Forum

CBI will once again host the industry’s only 340B Closed-Door Forum in tandem with its 340B Manufacturer Summit. This forum convenes manufacturers and covered entities to discuss innovative methods for collaboration under the 340B program. For more information or to apply to participate in this exclusive session, please contact CBI’s 340B Lead, Emily Stone, at [email protected].

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of
opportunities to network with attendees.

President, Apexus

Outstanding conference for me as a new person to 340B.

Regional Account Manager, Helsinn Therapeutics

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

340B Manufacturer Summit

Strategies and Best Practices to Strengthen Program Compliance and Integrity in an Evolving Regulatory Landscape

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 4th Annual 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes, and establish best practices to collaborate with contract pharmacies and covered entities.

Along with convening 340B manufacturers, CBI’s summit is also the only event to convene manufacturers and covered entities within our Closed-Door Collaboration Summit to discuss innovative methods to work together under the 340B program.

Don’t miss out on the industry’s premiere event to propel collaborative initiatives, adhere to new and evolving regulatory guidance and mitigate risk within a highly complex market.

Critical Updates, Interactive Discussions
and Valuable Takeaways:

  • Gain key insights on 340B program developments and
    anticipated future rulings
  • Improve understanding of self-disclosure letters to
    effectively respond and resolve financial discrepancies
  • Discuss covered entity and pharmacy challenges and
    best practices for collaboration
  • Hear relevant case studies on manufacturer successes
    and lessons learned related to implementing new guidance
    and price calculations
  • Explore auditing best practices to pinpoint payment
    discrepancies and maintain strong covered entity relationships
  • Interpret HRSA guidance and government regulations to
    define patients and calculate AMP and best price

CBI’s 340B Manufacturer Summit hosts the 340B Closed-Door Collaboration Forum

CBI will once again host the industry’s only 340B Closed-Door Forum in tandem with its 340B Manufacturer Summit. This forum convenes manufacturers and covered entities to discuss innovative methods for collaboration under the 340B program. For more information or to apply to participate in this exclusive session, please contact CBI’s 340B Lead, Emily Stone, at [email protected].

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of
opportunities to network with attendees.

President, Apexus

Outstanding conference for me as a new person to 340B.

Regional Account Manager, Helsinn Therapeutics

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson